The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score
Open accessAbstract
BACKGROUND & AIMS: Immunotherapy with atezolizumab plus bevacizumab represents the new standard of care in systemic front-line treatment of hepatocellular carcinoma (HCC). However, biomarkers that predict treatment success and survival remain an unmet need. METHODS: Patients with HCC put on PD-(L)1-based immunotherapy were included in a training set (n = 190; 6 European centers) and a validation set (n = 102; 8 European centers). We investigated the prognostic value of baseline variables on overall survival using a Cox model in the training set and developed the easily applicable CRAFITY (CRP and AFP in ImmunoTherapY) score. The score was validated in the independent, external cohort, and evaluated in a cohort of patients treated with sorafenib (n = 204). RESULTS: Baseline serum alpha-fetoprotein ≥100 ng/ml (hazard ratio [HR] 1.7; p = 0.007) and C-reactive protein ≥1 mg/dl (HR, 1.7; p = 0.007) were identified as independent prognostic factors in multivariable analysis and were used to develop the CRAFITY score. Patients who fulfilled no criterion (0 points; CRAFITY-low) had the longest median overall survival (27.6 (95% CI 19.5-35.8) months), followed by those fulfilling 1 criterion (1 point; CRAFITY-intermediate; 11.3 (95% CI 8.0-14.6) months), and patients meeting both criteria (2 points; CRAFITY-high; 6.4 (95% CI 4.8-8.1) months; p <0.001). Additionally, best radiological response (complete response/partial response/stable disease/progressive disease) was significantly better in patients with lower CRAFITY score (CRAFITY-low: 9%/20%/52%/20% vs. CRAFITY-intermediate: 3%/25%/36%/36% vs. CRAFITY-high: 2%/15%/22%/61%; p = 0.003). These results were confirmed in the independent validation set and in different subgroups, including Child-Pugh A and B, performance status 0 and ≥1, and first-line and later lines. In the sorafenib cohort, CRAFITY was associated with survival, but not radiological response. CONCLUSIONS: The CRAFITY score is associated with survival and radiological response in patients receiving PD-(L)1 immunotherapy. The score may help with patient counseling but requires prospective validation. LAY SUMMARY: The immunotherapy-based regimen of atezolizumab plus bevacizumab represents the new standard of care in systemic first-line therapy of hepatocellular carcinoma (HCC). Biomarkers to predict treatment outcome are an unmet need in patients undergoing immunotherapy for HCC. We developed and externally validated a score that predicts outcome in patients with HCC undergoing immunotherapy with immune checkpoint blockers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Meng, W., Li, X., Bai, Z., Li, Y., Yuan, J., Liu, T., Yan, J., Zhou, W., Zhu, K., Zhang, H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090660 · Cited by 43
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Austin, P. C. (2011) · Multivariate Behavioral Research · doi:10.1080/00273171.2011.568786 · Cited by 12,242
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Assessing the Performance of Prediction Models: A Framework for Traditional and Novel Measures
Steyerberg, E. W., Vickers, A. J., Cook, N. R., Gerds, T., Gonen, M., Obuchowski, N., Pencina, M. J., & Kattan, M. W. (2010) · Epidemiology · doi:10.1097/ede.0b013e3181c30fb2 · Cited by 5,170
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Lencioni, R., & Llovet, J. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247132 · Cited by 4,329
A note on quantifying follow-up in studies of failure time
Schemper, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,575
Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479
Self-citationCancer-related inflammation and treatment effectiveness
Diakos, C. I., Charles, K. A., McMillan, D. C., & Clarke, S. J. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70263-3 · Cited by 2,193
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Gender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production
Naugler, W. E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A. M., & Karin, M. (2007) · Science · doi:10.1126/science.1140485 · Cited by 1,955
Towards better clinical prediction models: seven steps for development and an ABCD for validation
Steyerberg, E. W., & Vergouwe, Y. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu207 · Cited by 1,928
Finn, R. S., Ryoo, B.-Y., Merle, P., Kudo, M., Bouattour, M., Lim, H. Y., Breder, V., Edeline, J., Chao, Y., Ogasawara, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01307 · Cited by 1,789
Park, E. J., Lee, J. H., Yu, G.-Y., He, G., Ali, S. R., Holzer, R. G., Österreicher, C. H., Takahashi, H., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2009.12.052 · Cited by 1,764
Zhu, A. X., Kang, Y.-K., Yen, C.-J., Finn, R. S., Galle, P. R., Llovet, J. M., Assenat, E., Brandi, G., Pracht, M., Lim, H. Y., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30937-9 · Cited by 1,662
Uno, H., Cai, T., Pencina, M. J., D'Agostino, R. B., & Wei, L. J. (2011) · Statistics in Medicine · doi:10.1002/sim.4154 · Cited by 1,535
McMillan, D. C. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.08.003 · Cited by 1,398
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Pfister, D., Núñez, N. G., Pinyol, R., Govaere, O., Pinter, M., Szydlowska, M., Gupta, R., Qiu, M., Deczkowska, A., Weiner, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03362-0 · Cited by 1,294
Self-citationIdentification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Sia, D., Jiao, Y., Martinez-Quetglas, I., Kuchuk, O., Villacorta-Martin, C., Castro de Moura, M., Putra, J., Camprecios, G., Bassaganyas, L., Akers, N., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.007 · Cited by 976
Duvoux, C., Roudot–Thoraval, F., Decaens, T., Pessione, F., Badran, H., Piardi, T., Francoz, C., Compagnon, P., Vanlemmens, C., Dumortier, J., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.052 · Cited by 955
Mazzaferro, V., Sposito, C., Zhou, J., Pinna, A. D., De Carlis, L., Fan, J., Cescon, M., Di Sandro, S., Yi-feng, H., Lauterio, A., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.09.025 · Cited by 655
Yau, T., Park, J. W., Finn, R. S., Cheng, A.-L., Mathurin, P., Edeline, J., Kudo, M., Han, K.-H., Harding, J. J., Merle, P., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.029 · Cited by 647
Biology and significance of alpha-fetoprotein in hepatocellular carcinoma
Galle, P. R., Foerster, F., Kudo, M., Chan, S. L., Llovet, J. M., Qin, S., Schelman, W. R., Chintharlapalli, S., Abada, P. B., Sherman, M., et al. (2019) · Liver International · doi:10.1111/liv.14223 · Cited by 597
Sangro, B., Melero, I., Wadhawan, S., Finn, R. S., Abou-Alfa, G. K., Cheng, A.-L., Yau, T., Furuse, J., Park, J.-W., Boyd, Z., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.07.026 · Cited by 407
The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review
Pinter, M., Jain, R. K., & Duda, D. G. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.3381 · Cited by 339
Self-citationFinn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Lim, H. Y., Kudo, M., Breder, V. V., Merle, P., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.3_suppl.267 · Cited by 319
Cancer and liver cirrhosis: implications on prognosis and management
Pinter, M., Trauner, M., Peck-Radosavljevic, M., & Sieghart, W. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000042 · Cited by 295
Self-citationGaining more flexibility in Cox proportional hazards regression models with cubic spline functions
Heinzl, H., & Kaider, A. (1997) · Computer Methods and Programs in Biomedicine · doi:10.1016/s0169-2607(97)00043-6 · Cited by 283
Self-citationImmunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups
Pinter, M., Scheiner, B., & Peck-Radosavljevic, M. (2021) · Gut · doi:10.1136/gutjnl-2020-321702 · Cited by 233
Self-citationAlpha-fetoprotein: a renaissance
Terentiev, A. A., & Moldogazieva, N. T. (2013) · Tumor Biology · doi:10.1007/s13277-013-0904-y · Cited by 181
Pinato, D. J., Stebbing, J., Ishizuka, M., Khan, S. A., Wasan, H. S., North, B. V., Kubota, K., & Sharma, R. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.06.022 · Cited by 181
Self-citationReview article: systemic treatment of hepatocellular carcinoma
Pinter, M., & Peck‐Radosavljevic, M. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14913 · Cited by 160
Self-citationHucke, F., Pinter, M., Graziadei, I., Bota, S., Vogel, W., Müller, C., Heinzl, H., Waneck, F., Trauner, M., Peck-Radosavljevic, M., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.07.002 · Cited by 159
Self-citationSieghart, W., Pinter, M., Hucke, F., Graziadei, I. W., Schöniger–Hekele, M., Müller, C., Vogel, W., Trauner, M., & Peck‐Radosavljevic, M. (2012) · Hepatology · doi:10.1002/hep.26057 · Cited by 138
Self-citationScheiner, B., Kirstein, M. M., Hucke, F., Finkelmeier, F., Schulze, K., von Felden, J., Koch, S., Schwabl, P., Hinrichs, J. B., Waneck, F., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15245 · Cited by 136
Self-citationYang, J., Wezeman, M. J., Zhang, X., Lin, P., Wang, M. L., Qian, J., Wan, B., Kwak, L. W., Yu, L., & Yi, Q. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.008 · Cited by 120
Riedl, J. M., Barth, D. A., Brueckl, W. M., Zeitler, G., Foris, V., Mollnar, S., Stotz, M., Rossmann, C. H., Terbuch, A., Balić, M., et al. (2020) · Cancers · doi:10.3390/cancers12082319 · Cited by 115
Iivanainen, S., Ahvonen, J., Knuuttila, A., Tiainen, S., & Koivunen, J. P. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000531 · Cited by 105
C reactive protein impairs adaptive immunity in immune cells of patients with melanoma
Yoshida, T., Ichikawa, J., Giuroiu, I., Laino, A. S., Hao, Y., Krogsgaard, M., Vassallo, M., Woods, D. M., Hodi, F. S., & Weber, J. S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000234 · Cited by 104
Pardee, A. D., Shi, J., & Butterfield, L. H. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400725 · Cited by 100
Shan, Y., Huang, Y., Xie, Y.-K., et al. (2010) · Medical Oncology · doi:10.1007/s12032-010-9600-6 · Cited by 94
Sanghera, C., Teh, J. J., & Pinato, D. J. (2019) · Liver International · doi:10.1111/liv.14220 · Cited by 88
Self-citationSpahn, S., Roessler, D., Pompilia, R., Gabernet, G., Gladstone, B. P., Horger, M., Biskup, S., Feldhahn, M., Nahnsen, S., Hilke, F. J., et al. (2020) · Cancers · doi:10.3390/cancers12123830 · Cited by 79
Self-citationTyson, G. L., Duan, Z., Kramer, J. R., Davila, J. A., Richardson, P., & El‐Serag, H. B. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.07.026 · Cited by 65
Maeda, S., Hikiba, Y., Sakamoto, K., Nakagawa, H., Hirata, Y., Hayakawa, Y., Yanai, A., Ogura, K., Karin, M., & Omata, M. (2009) · Hepatology · doi:10.1002/hep.23199 · Cited by 65
Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma
Takada, H., Kurosaki, M., Nakanishi, H., Takahashi, Y., Itakura, J., Tsuchiya, K., Yasui, Y., Tamaki, N., Takaura, K., Komiyama, Y., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198812 · Cited by 65
Akamine, T., Takada, K., Toyokawa, G., Kinoshita, F., Matsubara, T., Kozuma, Y., Haratake, N., Takamori, S., Hirai, F., Tagawa, T., et al. (2018) · Surgical Oncology · doi:10.1016/j.suronc.2018.01.002 · Cited by 61
El-Khoueiry, A. B., Melero, I., Yau, T. C., Crocenzi, T. S., Kudo, M., Hsu, C., Choo, S., Trojan, J., Welling, T. H., Meyer, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.4_suppl.475 · Cited by 56
Self-citationLaderoute, M. P., & Pilarski, L. M. (1995) · PubMed · Cited by 38
C-Reactive Protein Promotes the Expansion of Myeloid Derived Cells With Suppressor Functions
Jimenez, R. V., Kuznetsova, V., Connelly, A. N., Hel, Z., & Szalai, A. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02183 · Cited by 36
Meischl, T., Rasoul‐Rockenschaub, S., Györi, G., Sieghart, W., Reiberger, T., Trauner, M., Soliman, T., Berlakovich, G. A., & Pinter, M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0216677 · Cited by 31
Self-citationMorita, M., Tamiya, M., Fujimoto, D., Tamiya, A., Suzuki, H., Hirano, K., Fukuda, Y., Yokoyama, T., Kominami, R., Kanazu, M., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-6582-4 · Cited by 21
Hayashi, T., Shibata, M., Oe, S., Miyagawa, K., Honma, Y., & Harada, M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0244370 · Cited by 16
Mori, S., Kita, J., Kato, M., Shimoda, M., & Kubota, K. (2014) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2014.02.015 · Cited by 8
Cited by
Vogel, A., Meyer, T., Sapisochin, G., Salem, R., & Saborowski, A. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01200-4 · Cited by 2,427
Self-citationEASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Sangro, B., Argemi, J., Ronot, M., Paradis, V., Meyer, T., Mazzaferro, V., Jepsen, P., Golfieri, R., Galle, P., Dawson, L., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.028 · Cited by 985
Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors
Huang, D. Q., Mathurin, P., Cortez-Pinto, H., & Loomba, R. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00688-6 · Cited by 553
Precision treatment in advanced hepatocellular carcinoma
Yang, X., Yang, C., Zhang, S., Geng, H., Zhu, A. X., Bernards, R., Qin, W., Fan, J., Wang, C., & Gao, Q. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.01.007 · Cited by 429
Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma
Chan, Y.-T., Zhang, C., Wu, J., Lu, P., Xu, L., Yuan, H., Feng, Y., Chen, Z.-S., & Wang, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02101-z · Cited by 281
Metadata
- Authors
- Scheiner, B., Pomej, K., Kirstein, M. M., Hucke, F., Finkelmeier, F., Waidmann, O., Himmelsbach, V., Schulze, K., von Felden, J., Fründt, T. W., Stadler, M., Heinzl, H., Shmanko, K., Spahn, S., Radu, P., Siebenhüner, A. R., Mertens, J. C., Rahbari, N. N., Kütting, F., Waldschmidt, D.-T., Ebert, M. P., Teufel, A., De Dosso, S., Pinato, D. J., Pressiani, T., Meischl, T., Balcar, L., Müller, C., Mandorfer, M., Reiberger, T., Trauner, M., Personeni, N., Rimassa, L., Bitzer, M., Trojan, J., Weinmann, A., Wege, H., Dufour, J.-F., Peck-Radosavljevic, M., Vogel, A., & Pinter, M.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2022-02
- Volume
- 76
- Issue
- 2
- Pages
- 353-363
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W3205914248
- Cited by
- 303
- References
- 57
- FWCI
- 22.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.